Mayo Clinic experimental pancreatic cancer vaccine shows immune response

An experimental vaccine, camupepimut, triggered an immune response in 98.9% of evaluated patients during a phase 2 clinical trial, according to results published in Nature Medicine. The study involved 144 individuals with ductal adenocarcinoma of the pancreas, the most common form of the disease, who had previously undergone surgery and chemotherapy.

The vaccine is designed to train the immune system to recognize seven common mutations in the KRAS gene, which are present in approximately 90% of these pancreatic adenocarcinomas. By delivering fragments of these mutations to the lymph nodes, the treatment aims to stimulate T-cell activity against cancer cells.

While the trial showed significant success in activating defense cells, researchers noted that it has not yet conclusively proven that the vaccine reduces cancer recurrence or increases overall survival rates. Pancreatic cancer remains difficult to treat, with recurrence occurring in up to 80% of patients following standard procedures.